Eli Lilly Sets Guidance for 2023 and Stock Falls As EPS Lags Current Consensus

MarketWatch2022-12-13

Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
6